Inventor · disambiguated record
Mark J. Selby
Also filed as: SELBY MARK · SELBY MARK J
88 granted patents·55 pending applications·6,595 citations·filing 1995–2025
99Inventor score
Files withBRISTOL MYERS SQUIBB CO57SQUIBB & SONS LLC29CHIRON CORP19NOVARTIS VACCINES & DIAGNOSTIC10MEDAREX INC5
Top patents by PatentIndex Score
143 records- 0199US10441655B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2016·Granted Oct 15, 2019·25 cites·22 claims
- 0299US9580507B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2016·Granted Feb 28, 2017·129 cites·30 claims
- 0399US9492539B2Monoclonal antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·119 cites·65 claims
- 0499US9492540B2Methods for treating cancer using anti-PD-1 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·139 cites·79 claims
- 0599US9387247B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Jul 12, 2016·124 cites·45 claims
- 0699US9358289B2Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Jun 7, 2016·137 cites·49 claims
- 0799US9273135B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Mar 1, 2016·109 cites·30 claims
- 0899US9102725B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2013·Granted Aug 11, 2015·120 cites·31 claims
- 0999US8383796B2Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2011·Granted Feb 26, 2013·355 cites·31 claims
- 1099US8008449B2Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeuticsMEDAREX INC·Filed 2006·Granted Aug 30, 2011·2.2k cites·23 claims
- 1199US7943743B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2006·Granted May 17, 2011·1.5k cites·26 claims
- 1298US11001630B2Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted May 11, 2021·10 cites·20 claims
- 1398US10988536B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted Apr 27, 2021·10 cites·20 claims
- 1498US10344089B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2017·Granted Jul 9, 2019·25 cites·20 claims
- 1598US9580505B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Feb 28, 2017·37 cites·41 claims
- 1698US9228016B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 5, 2016·85 cites·19 claims
- 1798US9084776B2Methods for treating cancer using anti-PD-1 antibodiesMEDAREX LLC·Filed 2014·Granted Jul 21, 2015·203 cites·9 claims
- 1898US8779105B2Monoclonal antibodies to programmed death 1 (PD-1)KORMAN ALAN J·Filed 2011·Granted Jul 15, 2014·479 cites·30 claims
- 1997US11530267B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Dec 20, 2022·2 cites·21 claims
- 2097US11236165B2Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 2197US11236163B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 2297US11236164B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 2397US10501550B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 10, 2019·9 cites·58 claims
- 2497US10465010B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Nov 5, 2019·9 cites·15 claims
- 2597US10251945B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 9, 2019·20 cites·28 claims
- 2697US10196445B1Ipilimumab variant with enhanced ADCCBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Feb 5, 2019·22 cites·11 claims
- 2797US9745379B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Aug 29, 2017·11 cites·58 claims
- 2896US11512130B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Nov 29, 2022·2 cites·22 claims
- 2996US11274152B2Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 15, 2022·6 cites·12 claims
- 3096US10988535B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2019·Granted Apr 27, 2021·10 cites·20 claims
- 3196US8609816B2Human monoclonal antibodies to O8EKORMAN ALAN J·Filed 2006·Granted Dec 17, 2013·42 cites·26 claims
- 3294US12312403B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Granted May 27, 2025·1 cites·17 claims
- 3394US11084881B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Aug 10, 2021·3 cites·19 claims
- 3494US10898556B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 26, 2021·7 cites·22 claims
- 3594US10077306B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 18, 2018·7 cites·22 claims
- 3694US7888004B2HCV non-structural polypeptideNOVARTIS VACCINES & DIAGNOSTIC·Filed 2008·Granted Feb 15, 2011·11 cites·13 claims
- 3794US6602705B1Expression of HIV polypeptides and production of virus-like particlesCHIRON CORP·Filed 1999·Granted Aug 5, 2003·144 cites·39 claims
- 3893US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 3993US11207391B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 28, 2021·4 cites·20 claims
- 4093US10533052B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 14, 2020·4 cites·30 claims
- 4193US10081681B2Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Sep 25, 2018·17 cites·18 claims
- 4293US8563694B2Fully human antibodies to BTLAMATARAZA JENNIFER MARIE·Filed 2010·Granted Oct 22, 2013·39 cites·8 claims
- 4393US6521423B1Intracellular production of Hepatitis C E2 polypeptidesCHIRON CORP·Filed 2000·Granted Feb 18, 2003·32 cites·13 claims
- 4492US12037604B2Modified B cells and methods of use thereofWALKING FISH THERAPEUTICS·Filed 2023·Granted Jul 16, 2024·4 cites·17 claims
- 4592US11913023B2Modified B cells and methods of use thereofWALKING FISH THERAPEUTICS·Filed 2021·Granted Feb 27, 2024·4 cites·32 claims
- 4692US10690674B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 23, 2020·5 cites·27 claims
- 4792US6986892B1Immunogenic Hepatitis C virus non-structural polypeptidesCHIRON CORP·Filed 2000·Granted Jan 17, 2006·35 cites·19 claims
- 4892US6562346B1Activation of HCV-specific T cellsCHIRON CORP·Filed 2000·Granted May 13, 2003·43 cites·26 claims
- 4991US10653791B2Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 19, 2020·10 cites·6 claims
- 5091US10493140B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 3, 2019·3 cites·21 claims
Showing the top 50 of 143 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark J. Selby files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →